On this unique MedPage Right now video, Tanya Dorff, MD, of Metropolis of Hope in Duarte, California, discusses two prostate most cancers immunotherapy research offered on the latest American Society of Medical Oncology (ASCO) annual assembly.
Following is a transcript of her remarks:
There have been two attention-grabbing prostate most cancers immunotherapy research at this assembly offered within the speedy oral session. One was the tarlatamab (Imdelltra) research. It is a bispecific T-cell engager focusing on DLL3 for neuroendocrine prostate most cancers. Sadly, the response charge was comparatively low and the speed of cytokine launch syndrome was pretty excessive — what we’re used to seeing with different bispecific antibodies on this illness. So it is unlikely that this can turn into a therapeutic that we will use for this inhabitants that is an incredible unmet want.
However the different antibodies which can be T-cell partaking which can be getting used for adenocarcinoma, the prostate, issues like AMG 160, which we not too long ago printed in Medical Most cancers Analysis, and the continuing AMG 509, do appear to have larger ranges of efficacy. So it is a modality that I believe will come for use within the clinic in prostate most cancers remedy sooner or later.
The opposite actually attention-grabbing summary was NEPTUNES, which was utilizing an immune choice biomarker to deal with sufferers with mCRPC [metastatic castration-resistant prostate cancer] with [ipilimumab (Yervoy)-nivolumab (Opdivo)]. So beforehand ipi-nivo has been troublesome to tolerate in mCRPC and never as efficient as we wish, however this immune choice biomarker appears to have executed job. The response charge was significantly higher, about 44%. Toxicity was extra manageable on this inhabitants for no matter cause.
However, nonetheless, I believe there are different selectors that folks ought to keep in mind. So we not too long ago printed that for prime tumor mutational burden, which is on-label for pembrolizumab [Keytruda], about 50% of mCRPC sufferers with that biomarker reply to single agent, which has a a lot better toxicity profile.
